Omalizumab in patients with severe asthma and persistent sputum eosinophilia

[1]  P. O'Byrne,et al.  Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma. , 2015, The Journal of allergy and clinical immunology.

[2]  L. Boulet,et al.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. , 2014, The New England journal of medicine.

[3]  S. Walker,et al.  Omalizumab for asthma in adults and children. , 2014, The Cochrane database of systematic reviews.

[4]  L. Thabane,et al.  Sample sizes for clinical trials using sputum eosinophils as a primary outcome , 2013, European Respiratory Journal.

[5]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[6]  Stephen T Holgate,et al.  Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. , 2004, American journal of respiratory and critical care medicine.

[7]  P. O'Byrne,et al.  The effect of pranlukast on allergen-induced bone marrow eosinophilopoiesis in subjects with asthma. , 2004, American journal of respiratory and critical care medicine.